Podcasts about cyclosporine

There have been so many wonderful tools added to our management of allergic dermatitis in dogs over the last decade. Apoquel, Cytopoint and Zenrelia have all been medications that provide quick itch relief with a more targeted approach. However, the use of cyclosporine as an option (except for cats where it is prescribed more frequently) has dwindled. Though these new tools have revolutionized our field, allergic dermatitis is complicated and there are still some cases that respond better to cyclosporine. So, when should you consider reaching cyclosporine in allergic management? Check out this week's episode of The Derm Vet podcast to find out!TIMESTAMPS00:00 Intro00:25 Cyclosporine02:27 Why choose Cyclosporine for Dogs with allergies08:44 Weird Issues with Cyclosporine11:55 Cats and Cyclosporine13:36 What's available in the U.S. for Cyclosporine  15:26 Other forms of Cyclosporine18:53 Summary

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! On this episode of the Top 200 drugs podcast, we are going to cover these 5 medications: Cyclosporine, insulin glargine, tadalafil, amitriptyline, and gemfibrozil. Cyclosporine is a calcineurin inhibitor that suppresses the immune system. This is useful in patients who have had an organ transplant. Insulin glargine is a long-acting insulin product that can be used in type 1 and type 2 diabetes. I discuss adverse effects, dosing, and much more. Tadalafil is a PDE-5 inhibitor that can be used to treat sexual dysfunction. The nitrate drug interaction is one of the most highly tested drug interactions in school. Amitriptyline is a TCA. It is highly anticholinergic and because of this is not a great medication to utilize in elderly patients. Gemfibrozil is primarily used to lower triglyceride levels. This medication can significantly increase the risk for rhabdomyolysis in patients taking statin medications.

Luckily, veterinarians have an arsenal of medications available to treat dermatology conditions in their patients, including Apoquel (oclacitinib) for immediate itch relief during allergy flares, Cytopoint (lokivetmab) for dogs with difficulty taking pills or when needing longer-lasting itch control, and cyclosporine for more severe cases that require a stronger immunosuppressive response. In this VetFolio Voice podcast episode, Dr. Cassi and Dr. Watson explore the use of these drugs in managing dermatology cases. You'll learn when cyclosporine is most likely to be helpful and how to dose it — in particular, starting with a low dose and adjusting the dose up, giving with food to reduce GI upset, and giving with ketoconazole to help lower the dose of cyclosporine needed. You'll also get insights into potential side effects and how to address them. Dr. Cassi and Dr. Watson take a look at the role of diet, allergy testing and immunotherapy in managing these cases, as well as emphasize the importance of referral in veterinary dermatology and the importance of early referral for successful management of these cases. e sure to log into VetFolio and take the quiz to qualify for your CE credit! https://www.vetfolio.com/courses/stop-snoring-on-cyclosporine-podcast-quiz

Living with pustular psoriasis is tough. Hear the latest updates about heritable aspects of GPP, diagnosis, management tips, and treatment options such as the IL-36 inhibitor spesolimab, how it works and how effective it is from dermatologist Dr. Laura Ferris, Professor of Dermatology at the University of Pittsburgh and moderator Alan Simmons. This episode is provided with support from our Psoriasis Action Month sponsors. 

Yes, there are more options than antihistamines to treat chronic spontaneous urticaria. We dive into them!  Dr. Sheila Gogate joins us to discuss the chronic spontaneous urticaria (CSU) treatments currently available for patients. Dr. Shaila Gogate outlines the treatment journey for CSU with an emphasis on shared decision-making.   This episode emphasizes the importance of following treatment guidelines and adjusting medications as needed. We discuss the available treatments for urticaria, including antihistamines, omalizumab (Xolair for hives), and Cyclosporine. The episode also explores the journey of managing CSU symptoms through both medical and non-medical approaches. What we cover in our episode about chronic spontaneous urticaria treatments Treatment Path and Guidelines: Overview of doctors' steps to treat CSU. The importance of shared decision-making in the treatment plan.  Antihistamines: Role of oral antihistamines and H2 blockers in managing hives, dosing options, side effects, when to change medications, and how to choose the right antihistamine. Advanced Treatments: If antihistamines fail, the following steps include omalizumab (Xolair) injections or Cyclosporine. An overview of both dosing options and side effects. Emerging Therapies: Treatments like Remibrutinib and Dupilumab. Quality of Life and Non-Medical Management: The Urticaria Activity Score (UAS7). Mental health screening for CSU patients and strategies like stress reduction and if special diets are effective. About our guest, Dr. Shaila Gogate Dr. Shaila Gogate, board-certified by the American Board of Allergy & Immunology, has been with Colorado Allergy & Asthma Centers since 2014. She completed her medical education at Chicago Medical School, her residency at Washington University, and her fellowship at National Jewish Health in Denver. Dr. Gogate has served as an Assistant Professor at the University of Colorado, has extensive clinical research experience, and emphasizes strong patient-provider communication to develop effective treatment plans. More resources about chronic spontaneous urticaria:  Chronic Urticaria Management, Resources & Glossary of Terms: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/management-and-resources/ What is Chronic Urticaria: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/  How Mast Cells Work Video_ mast cell video - explanation of mast cell (07:20): https://youtu.be/OF7tBIvMK_0?si=osJaIpTrivUP1Owr Urticaria Activity Score (uas7): https://www.mdcalc.com/calc/10226/urticaria-activity-score-uas More information about XOlair: https://www.xolair.com/chronic-spontaneous-urticaria.html

Harrow recently conducted an earnings call, where CEO Mark L. Baum communicated to investors: "Cyclosporine, without a doubt, is the most trusted active ingredient for U.S. dry eye disease patients. Eye care professionals trust cyclosporine. So do payers and patients. The VEVYE train is rolling with all of our key performance metrics moving positively. My word, VEVYE will benefit millions of U.S. dry eye disease patients in the long run and generate significant value for Harrow stockholders." Harrow, based on figures from 2023, has made notable strides in the ophthalmic pharmaceutical sector. A major part of these achievements is the successful introduction of products such as VEVYE, Triesence, and IHEEZO. Particularly, VEVYE's launch was a standout, with early customer feedback indicating robust market potential for this product. Similarly, the company's commitment to innovation and customer satisfaction was evident with significant positive impacts on surgical protocols from Triesence and IHEEZO, especially in relation to anesthesia. The company's products appear to resonate with key players in the market, including patients, eye care professionals, and payers. This is supported by positive responses on social media platforms and growing trust in cyclosporine products. The capacity of IHEEZO to reduce opioid exposure has also received favorable reception. CEO Mark L. Baum also announced a significant development: "I mentioned the news that we received from CMS yesterday, which allows IHEEZO, our low viscosity patented topical anesthetic gel, to be separately payable and reimbursable in the physician's office." This is another feather in Harrow's cap, expanding the potential market for IHEEZO and allowing Medicare beneficiaries to avail the product's unique benefits. As we approach 2024, Harrow seems geared for growth. The year's projected revenue, a planned investment in sales, and marketing for products such as VEVYE and IHEEZO suggest a growth-focused strategy. But it's worth reminding that these are plans, and the company's trajectory will depend on the business environment, market dynamics, and the company's execution of these plans. Early advancements around IHEEZO indicate potential for growth. To conclude, the latest earnings call signals that Harrow is well-positioned to respond to opportunities in the ophthalmic pharmaceutical marketplace. However, the emphasis should be on the point that these are projections or estimations based on current data and any number of unforeseen changes in the marketplace could alter the outlook. NULL Company info: https://finance.yahoo.com/quote/NULL/profile For more PSFK research : www.psfk.com  This email has been published and shared for the purpose of business research and is not intended as investment advice.

There are many causes for pododermatitis... how do you assure you work these cases up the right way? If it is due to underlying allergies, which treatments tend to be more successful?Check out this week's episode of The Derm Vet podcast!

The Filtrate:Joel TopfSwapnil HiremathSophia AmbrusoAC GomezJosh WaitzmanJennie LinNayan AroraThe CurbsidersMatt F. Watto (@DoctorWatto)Paul Nelson Williams, America's primary care physician (@PaulNWilliamz)With Special Guest:JD Foster (@KidneyVet)Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital SignsMichelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX TrialEditor:Joel TopfShow Notes:Lily toxicity in the cat (PubMed)Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News)Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed)Nephrology in Veterinary Medicine (Kidney 360)Star Wars Society of San Antonio (FaceBook)These Vital Signs (Amazon)Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader)The pearl not the patient (PubMed)Late Braking and High Impact Clinical Trial press releaseMENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM)KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM)Sophie's number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet)Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058).Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD)AC Gomez's Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org) Josh's Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM)Nayan's Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine) The Freely Filtered simultaneous release (NephJC)Freely Filtered is now a verb. Swap's Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org)Joel's Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org)Reata is a no-show to the 2012 ASN Kidney Week (PBFluids)Michelle's Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM)DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)

Danielle and Elizabeth started chatting about cats in the rain - do they love it or hate it? Danielle mentioned that she has a new outdoor cat, and they revisited the idea of letting their cats go outside. Then Sarah Curcio was introduced, and she started with how she loves to adopt black animals. It runs in her family! She's also a pet sitter. Her latest cat, Mitzi, came from a hoarding situation, but she's well adjusted and she doesn't even want to go outside. Sarah talked about treating a cat's skin rash by switching its food to gluten free, and how her cat now is sensitive to chicken. Elizabeth talked about Max, and how he didn't have a food allergy, now he's on Zyrtech, Cyclosporine and Dexamethasone for itching. Sarah talked about how her boyfriend trained her cat with cat cookies. Cat cookies? They talked about cats loving treats, then went into how social cats are. Danielle asked everyone to join the FaceBook Community, The Jersey PodCats Community. The conversation went on, if you ever have a question for Danielle or Elizabeth they'll be happy to answer it. They love cats and people, so question away! Support the showThe Jersey PodCatshttp://thejerseypodcats.comhttps://youtube.com/@thejerseypodcatshttps://instagram.com/thejerseypodcatshttps://m.facebook.com/groups/thejerseypodcatsDanielle Woolley danielle@thejerseypodcats.comElizabeth Gearhart elizabeth@thejerseypodcats.comTommy's Catshttp://tommyscatsnj.orgPassage to Profithttp://passagetoprofitshow.com

Mr. Pierre Giguère and Dr. Swapnil Hiremath provide an overview of their study, "Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients," on behalf of their colleagues.

Mr. Pierre Giguère and Dr. Swapnil Hiremath provide an overview of their study, "Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients," on behalf of their colleagues.

Visit: https://nursing.com/140meds to request your free copy of "140 Must Know Meds" Generic Name Cyclosporine Trade Name Sandimmune Indication Prevention of rejection in transplantation, treatment of severe RA, management of ulcerative colitis Action Inhibits normal immune response primarily by decreasing the activity of T cells Therapeutic Class Immunosuppressant, antirheumatics (DMARD) Pharmacologic Class Polypeptides (cyclic) Nursing Considerations • May cause seizures, tremors, hypertension, hepatotoxicity, diarrhea, N/V, gingival hyperplasia • Increases immune suppression with corticosteroids • Avoid grapefruit juice while taking this medications • Assess for signs of organ rejection • Monitor renal panel, liver enzymes • Take medication as directed • Lifelong therapy required for transplant patients • Instruct pt on how to take blood pressure

Drs Sunanda Kane and Peter D. Higgins discuss the first 72 hours of inpatient UC care. What are best practices for diet and painkillers? When should your patient see a surgeon? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984006). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Ulcerative Colitis https://emedicine.medscape.com/article/183084-overview Efficacy and Safety of Biologics and Small Molecule Drugs for Patients With Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-analysis https://pubmed.ncbi.nlm.nih.gov/34856198/ Anti-TNF Therapy https://pubmed.ncbi.nlm.nih.gov/27726761/ Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy https://pubmed.ncbi.nlm.nih.gov/8196726/ Developing an Instrument to Assess the Endoscopic Severity of Ulcerative Colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) https://pubmed.ncbi.nlm.nih.gov/21997563/ Fecal Calprotectin https://pubmed.ncbi.nlm.nih.gov/30342711/ Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis https://pubmed.ncbi.nlm.nih.gov/30012431/ The Janus Kinases (Jaks) https://pubmed.ncbi.nlm.nih.gov/15575979/ Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis https://pubmed.ncbi.nlm.nih.gov/33319248/

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:  Practical use of the Molecular International Prognostic Scoring System  Mutational targets and other treatments in ongoing clinical trialsProphylaxis with venetoclax therapyBest practices for bone marrow transplant, including induction and salvage regimensTreatment options for hypoplastic myelodysplastic syndromesPresenters:Rami Komrokji, MDProfessorDepartment of Oncologic SciencesUniversity of South Florida  Vice ChairMalignant Hematology DepartmentMoffitt Cancer CenterTampa, FloridaMaría Díez Campelo, MD, PhDAssociate ProfessorDepartment of MedicineSchool of MedicineUniversity of SalamancaHematologistDepartment of HematologyUniversity Hospital of SalamancaSalamanca, SpainAmer Zeidan, MBBS, MHSAssociate Professor, Internal MedicineHematologyLeader, Leukemia and Myeloid Disease Aligned Research Team (DART)Director, Hematology Early Therapeutics ResearchYale Cancer Center and Smilow Cancer HospitalYale University School of MedicineNew Haven, ConnecticutLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:http://bit.ly/3YXgKK3  

"Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis." Gallo, Giuseppe, et al. Dermatologic Therapy (2022): e15917."Strategies for the Enhancement of Nail Plate Permeation of Drugs to Treat Onychomycosis." Gupta, Aditya K., et al. Journal of the European Academy of Dermatology and Venereology (2022).

Download the cheat: https://bit.ly/50-meds  View the lesson: https://bit.ly/CyclosporineSandimmuneNursingConsiderations    Generic Name Cyclosporine Trade Name Sandimmune Indication Prevention of rejection in transplantation, treatment of severe RA, management of ulcerative colitis Action Inhibits normal immune response primarily by decreasing the activity of T cells Therapeutic Class Immunosuppressant, antirheumatics (DMARD) Pharmacologic Class Polypeptides (cyclic) Nursing Considerations • May cause seizures, tremors, hypertension, hepatotoxicity, diarrhea, N/V, gingival hyperplasia • Increases immune suppression with corticosteroids • Avoid grapefruit juice while taking this medications • Assess for signs of organ rejection • Monitor renal panel, liver enzymes • Take medication as directed • Lifelong therapy required for transplant patients • Instruct pt on how to take blood pressure

Listen as dermatologist Dr. Laura Ferris, Professor of Dermatology at the University of Pittsburgh, joins us to talk about the primary types of skin cancer, how it compares to psoriasis, risk factors (including those associated with medications), diagnosis, treatments, and steps to protect your skin while in the sun. Psound Bytes is supported by unrestricted educational grants from AbbVie, Amgen, Bristol Myers Squibb and Janssen. 

Directly from the Vascular Annual Meeting in 2021 in San Diego, here's a taste of some of the great things that are happening at this year's VAM.  Hear perspectives from some first-time VAM attendees, as well as speakers, moderators, and other leaders in the field.     In this episode, we hear from Dr. Alan Dardik on the brand-new JVS: Vascular Science journal, which is the latest addition to the JVS family of publications.  We discuss the frontiers of vascular physiology, the scope of basic science beyond the wet lab, and his favorite articles from the journal to date.   Show Guests: Dr. Alan Dardik (@adardik) is a surgeon-scientist, and a professor of Surgery (Vascular) and of Cellular and Molecular Physiology at the Yale School of Medicine.  He leads the NIH-funded and VA-funded Dardik lab to study the healing and function of blood vessels and blood vessel substitutes used to treat patients with vascular disease, and is the editor of the JVS: Vascular Science journal.  He completed his MD/PhD, general surgery residency, and vascular surgery fellowship all at the Johns Hopkins University.   Relevant Resources: JVS: Vascular Science: https://jvsvs.org/ Inaugural issue cover article: https://doi.org/10.1016/j.jvssci.2020.09.004 JVS: VS May 2021 webinar: https://www.youtube.com/watch?v=xaByfdcOxRU Dardik Lab webpage: https://medicine.yale.edu/lab/dardik/ Cyclosporine and AVF article: https://doi.org/10.1161/ATVBAHA.120.315875 Vascular Research Initiatives Conference (VRIC): https://vascular.org/meetings/vascular-research-initiatives-conference-vric Previous Audible Bleeding Basic Science Episode: https://www.audiblebleeding.com/getting-started-in-basic-science/   Host Introductions:  Dr. Chris Audu (@ChrisAuduMD) is in his 5th year of training in the integrated vascular surgery residency at the University of Michigan. His research studies the role of chromatin modifying enzymes on wound healing pathways as well as learning the details of high throughput experimentation in discovering novel acid-amine organic reactions for vascular-focused, medicinal chemistry. He is currently F32 funded and was recently awarded the 2020 VESS Resident Research Award. Dr. Matt Chia (@chia_md) is in his 6th year in the integrated vascular surgery program at Northwestern University. He obtained his medical degree from the University of Illinois College of Medicine, and also holds a Master's in Health Services and Outcomes Research at Northwestern.    Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.

On this episode, I discuss cyclosporine pharmacology. This medication is an immunosuppressant used to reduce the risk of transplant rejection. Cyclosporine has a long list of potential adverse effects such as hyperglycemia, renal impairment, GI toxicity, and hypertriglyceridemia. Important monitoring parameters for cyclosporine include drug levels, electrolytes, renal function, and blood sugars. CYP3A4 interactions are critical with cyclosporine. Inhibitors can raise concentrations and inducers can lower concentrations.

This episode covers cyclosporine!

Cyclosporine and SJS - HTN leads to inconsequential bleeding in Mohs - Hydroxychloroquine for morphea - Omadacycline for skin infections - Suture spacing doesn't matter on the head and neck - Tattoos and risky behaviors Go to www.dermaspherepodcast.com for links to the original articles!

Dr. Michele Ramien talks with JCMS editor-in-chief Dr. Kirk Barber about the article she co-authored in the Nov-Dec 2019 issue of the Journal of Cutaneous Medicine and Surgery. In their conversation, Michele describes to Kirk the potential efficacy of cyclosporine A in the treatment of Mycoplasma pneumoniae-induced rash and mucositis, also known as MIRM. MIRM is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin.Dr Ramien is a clinical associate professor of dermatology and community pediatrics at the University of Calgary. She is also vice chair of the Camp Liberté Society, a camp for children with skin disorders.Music is by Lee Rosevere.JCMS Author Interviews is Produced by David McGuffin of Explore Podcast Productions in Ottawa.davidrcmcguffin@gmail.com  

Dr. Michele Ramien talks with JCMS editor-in-chief Dr. Kirk Barber about the article she co-authored in the Nov-Dec 2019 issue of the Journal of Cutaneous Medicine and Surgery. In their conversation, Michele describes to Kirk the potential efficacy of cyclosporine A in the treatment of Mycoplasma pneumoniae-induced rash and mucositis, also known as MIRM. MIRM is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin. Dr Ramien is a clinical associate professor of dermatology and community pediatrics at the University of Calgary. She is also vice chair of the Camp Liberté Society, a camp for children with skin disorders. Music is by Lee Rosevere. JCMS Author Interviews is Produced by David McGuffin of Explore Podcast Productions in Ottawa. davidrcmcguffin@gmail.com    

Learn how to make low-carb holiday meals and desserts that will wow your friends and family this holiday season: http://bit.ly/2C5hqpi In this show, Daniel Winkler is a world renowned-mushroom expert and has published several field guides to help us better identify edible and medicinal mushrooms. We discuss how mushrooms influence our immune system and offer key micronutrients essential to long-term health. Check out the show notes: https://highintensityhealth.com/251 Key Takeaways: 02:20 Mushrooms are seasonal, so your time to educate yourself on identifying mushrooms is very short. 03:10 Get to know the mushrooms that you want to use. Know any dangerous look-alikes. 11:10 The fruiting body of a mushroom is 90% water. 12:07 Mushrooms do not have a stomach. They are a mass of connected fine threads, a mesh. This forms a web called the mycelium. 12:33 Mushroom Sex: The part of the mushroom above ground is the reproductive organ of the mushroom. 14:23 The dried mushroom fruiting body is about 30% protein. 15:05 Mushrooms have powerful immune systems. 15:30 Mushrooms are also antibacterial and antiviral. 15:41 Medicinal mushrooms are those varieties with the most powerful immune systems. Examples are cordyceps, reishi and ganoderma. 17:21 Mushroom skin is made of the polysaccharide, chitin, like insects. 18:45 All vitamins can be found in mushrooms. 24:39 Smell and taste your mushrooms. Only swallow mushrooms that you know are edible and can be eaten raw. 25:48 In general, all mushrooms should be cooked. 26:54 Dry Frying: Fresh wet mushrooms can start cooking without oil. 30:13 Some mushrooms serve as an extension of the roots of a tree. Many trees take up to 90% of their water through the mushroom. The tree can return up to 60% of their sugars to the mushroom. 33:51 Mushrooms, lichens, eat rocks. 45:40 You can probably spread/seed mushrooms in your own yard in proper habitat by placing parts/pieces of fresh mushroom fruiting body. 50:44 Cordyceps grows a fruiting body out of a LIVE insect, taking over the insect’s movement with mycelium (like a puppet master), directing it into a place where it is optimal to spread its spores. 52:48 The drug Cyclosporine is made from a variety of cordyceps soil fungus. It suppresses your immune system, which is necessary for organ transplantation. 53:50 Other cordyceps support your immune system. 56:35 Some research shows that cordycepin stops cancer cell reproduction. It is also a powerful anti-inflammatory. 58:45 Mushrooms manage the echo system with what appears to be wisdom and planning. 01:06:20 Harvesting/using magic mushrooms is against the law. It is good to know how to identify them. 01:15:52 Lion’s Mane has been shown to help nerve cell regeneration and increases in memory of 10 to 15% in elderly people, and possibly impacts Parkinson’s symptoms. 01:23:18 Daniel believes that psychedelic mushrooms are less addictive than TV. 01:23:51 Psychedelics are showing use with alcoholism, drug addiction, PTSD and serious depression. 01:26:15 Psychedelics could be a trigger for people with the genetic predisposition of psychosis. Check out the show notes: https://highintensityhealth.com/251

Jack Gilbert talks about his studies on microbiomes of all sorts. He describes the origin of the Earth Microbiome Project, which has ambitions to characterize all microbial life on the planet, and talks more specifically about the built microbiome of manmade ecosystems such as hospitals. Gilbert explains how advances in scientific techniques have driven past microbiome-related discoveries and will continue to do so in the future. Host: Julie Wolf Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app. Julie's biggest takeaways: Insect-pathogenic fungi living in plant roots can pass nitrogen from killed insects to their plant hosts, receiving different carbon nutrients from the plants in return. Fungi harvested after growth on inexpensive materials like chicken droppings are used in agriculture both as fertilizer and as insecticide. Cyclosporine was first discovered in insect-pathogenic fungi. Raymond St. Leger and other scientists working to introduce genetically modified microbes into the environment deeply consider the societal effects of their work, including collaboration with local communities, governmental regulatory bodies, and trusted leaders and tailor their efforts to the regional area. Featured Quotes (in order of appearance): “We really can apply ecological understanding of microbiomes and microbial ecosystems to any environment.” “I think basic research is absolutely essential but I always want to think about what that could lead to in the future.” “Reproducibility is key and extraordinarily difficult in all fields of science due to lack of appropriate funding and a zeitgeist in science that discourages scientists from reproducing one another’s studies.” “We are forever striving to validate the predictions we derive from our descriptive work. We create SO MANY predictions!” “No small dreams, no small goals - go big or go home! At the end of the day, we all want to feel like we’re doing something that makes an impact.” “I love to collaborate. I love to work with other people, brilliant people in the microbiome field” “I’m often accused of not being focused enough. What does Jack Gilbert do? Well, I do a little bit of everything - as long as there’s a microbe involved! I like it like that; it keeps me energized.” Links for this episode Jack Gilbert website at University of Chicago Jack Gilbert TedxNaperville Talk Earth Microbiome Project home page Dirt is Good - new book by Gilbert and Rob Knight History of Microbiology Tidbit: Joshua Lederberg piece in The Scientist on ‘microbiome’ nomenclature in 2001. Send your stories about our guests and your comments (email or recorded audio) to jwolf@asmusa.org.

Raymond St. Leger describes his work on insect pathogenic fungi. Members of this diverse group of fungi can be found as part of the plant rhizosphere, where they provide nutrients to the plant, and can also be deployed as insect control agents. Raymond discusses his work with communities in Burkina Faso, where he works with officials to educate and gain consent for use of mosquito-killing fungi to control the spread of malaria. Host: Julie Wolf Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the Microbeworld app. Julie's biggest takeaways: Insect-pathogenic fungi living in plant roots can pass nitrogen from killed insects to their plant hosts, receiving different carbon nutrients from the plants in return. Fungi harvested after growth on inexpensive materials like chicken droppings are used in agriculture both as fertilizer and as insecticide. Cyclosporine was first discovered in insect-pathogenic fungi. Raymond St. Leger and other scientists working to introduce genetically modified microbes into the environment deeply consider the societal effects of their work, including collaboration with local communities, governmental regulatory bodies, and trusted leaders and tailor their efforts to the regional area. Featured Quotes: "Possibly fungi kill more organisms than any other disease-causing agents." (2:55) "People are interested in how you can utilize a plant-root colonizing Metarhizium as a comprehensive biofertilizer." (14:30) "Put elite Metarhizium onto corn seeds and you can boost the growth of corn by about 30%." (14:50) "Mosquitos and malaria have no friends." (23:17) "If an insect is especially common, then a strain of Metarhizium will specialize to that insect." (24:35) “There’s a lot of different ethical, political, and social concerns we have to address and we have to resolve before any type of genetically manipulated product can be introduced. We even have questions about the meaning of informed consent!" (28: 30) "Synbio-phobia-phobia: the belief that genetic engineers have that people are going to be frightened of their work."(32:00) "In Burkina Faso, you can expect to get more than 200 bites from Anopholes gambiae a day. This is malaria central." (37:58) Links for this episode Raymond St. Leger website at the University of Maryland St. Leger lab research explained in a three-minute video NPR story covering fungal pesticides as alternatives to chemicals Discover Magazine blog on malaria-fighting Frankenfungus CHOMA tidbit: Felix d'Herelle and the Origins of Molecular Biology by Bill Summers (Excerpt of Chapter 3. Epizootics: Locusts in Argentina and Algeria). Send your stories about our guests and/or your comments (email or recorded audio) to jwolf@asmusa.org.

  Carolyn: Welcome to Circulation On The Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Today we will be diving deep into issues of resistant hypertension, adherence to anti-hypertensive medication, and renal denervation. All this by looking closely at new data from the Renal Denervation for Hypertension trial. First, here are your summaries of this week's journal.     The first paper sought to answer these questions: How can we better re-stratify patients with long QT syndrome type 3? You will remember that as the type caused by a gain of function mutation in the SCN5A sodium channel, and the type that has a more lethal course than types 1 and 2. Another question is, are we sure that beta blockers are effective in type 3 long QT syndrome? Well the current study is by co-first-authors, Dr. Wilde of Academic Medical Center, Amsterdam, and Dr. Moss from University of Rochester School of Medicine and Dentistry, which is the largest multi-center long QT type 3 syndrome cohort described to date.     This study was designed to identify the risk and therapeutic factors associated with cardiac events in patients. The risk factors evaluated included clinical features such as age, gender, ECG measurements, the mutation type, and the therapeutic effects of beta blockers, other medications, and ICD. In almost four hundred patients with type 3 long QT syndrome, 30% experienced at least one cardiac event; that is syncope, aborted cardiac arrest, or sudden death. The risk of a first cardiac event was directly related to the degree of QT prolongation. Each 10 millisecond increase in QTC up to 500 milliseconds was associated with a 19% increase in cardiac events. Prior syncope doubled the risk of life threatening events. Beta blocker therapy was associated with an 83% percent reduction in cardiac events in females, however the efficacy in males could not be conclusively determined due to low number of events. The take-home message is, in your patients with long QT syndrome type 3, recognize the very high risk sub-population with prolonged QTC and a history of syncope.     The next paper is a basic science paper that reveals a novel way in which mitochondrial dysfunction may be targeted in heart failure. This paper is from first author Dr. Li, corresponding author Dr. Tian, and colleagues from the Mitochondria and Metabolism Center at University of Washington. These authors previously found that elevation in the NADH to NAD ratio induces mitochondrial protein hyperacetylation, and renders hearts highly susceptible to stresses, and they showed this in a mouse model of primary mitochondrial dysfunction caused by genetic defects. In the current study they defined the molecular intermediaries linking specific NAD sensitive hyperacetylation targets to the development of heart failure, and further demonstrated the relevance of these mechanisms in human heart failure. Specifically, they identified that hyperacetylation of the regulators of mitochondrial permeability transition poor and malate-aspartate shuttle, mediates the increased susceptibility to cardiac stresses. Further, expanding the cardiac NAD pool via pharmacological or genetic approaches normalized the NADH to NAD ratio, and thereby normalized protein acetylation in hypertrophied and failing hearts. Importantly, these measures improved cardiac function and reduced pathological hypertrophy in mice. Thus, the clinical implication is that restoring the NADH to NAD ratio may be an effective and translatable strategy to treat mitochondrial dysfunction in heart failure.     The next study broadens our considerations of the benefits versus risks of intensive anti-platelet therapy in patients with a prior myocardial infarction, and really suggests that more intensive anti-platelet therapy should be considered, not only to reduce the risks of coronary events, but also to reduce the risk of stroke. This is a paper from Dr. Bonaca and colleagues of the TIMI study group from Brigham and Women's Hospital in Boston, Massachusetts, who investigated the efficacy of ticagrelor, 60 milligrams twice a day, for reducing stroke in patients with a prior myocardial infarction from the Pegasus-TIMI 54 trial.     You will remember that in the Pegasus-TIMI 54 trial, ticagrelor was already shown to reduce the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior MI. Of more than 14,000 patients randomized to placebo or Ticagrelor, 213 experienced a stroke, 85% of which were ischemic. 18% of strokes were fatal, and another 15% led to either moderate or severe disability at 30 days. Ticagrelor significantly reduced the risk of stroke, with a hazards ratio of 0.75, and this was driven by a reduction in ischemic stroke. Hemorrhagic stroke occurred in nine patients on placebo and eight patients on ticagrelor. Furthermore, a meta-analysis of four placebo-controlled trials of more intensive antiplatelet therapy in more than 44,800 patients with coronary disease confirmed a marked reduction in ischemic stroke, with a combined hazards ratio of 0.66. Thus this study really broadens our considerations of benefits versus risks of intensive antiplatelet regimens for the long-term secondary prevention in patients with patients with prior myocardial infarction. It really highlights the broader benefits in reducing ischemic stroke, and not just coronary events. In summary, overall, for 1,000 patients initiated on ticagrelor 60 milligrams twice daily for three years, 13 primary endpoint events would be prevented, including approximately five ischemic strokes. This benefit would come at a cost of nine TIMI major bleeds, but no hemorrhagic strokes or fatal bleeds.     That wraps it up for our summaries! Now for our feature paper. Our feature paper today discusses a really important issue that we face everywhere around the world, and that is the management of resistant hypertension. We're taking a very interesting look at the Renal Denervation for Hypertension trial, because we're actually looking at the adherence to anti-hypertensive therapy, and what we've learned in this trial. I'm so excited because I am sitting right here with first and corresponding author Dr. Michel Azizi, from Georges Pompidou hospital in Paris, France. Hello Michel, thank you!   Michel: Hello, Carolyn. Thank you also for the invitation to discuss about the paper.   Carolyn: We're also so lucky to have the associate editor who handled the paper, Dr. Wanpen Vongpatanasin, associate editor from UT Southwestern. Welcome, Wanpen.   Wanpen: Hi, Carolyn.   Michel: Hi, Wanpen.   Carolyn: This whole issue of resistant hypertension, I'll tell you, to me that means someone who's adequately treated, and despite all the treatment that we can throw at them, they still have a blood pressure that is above a certain level, right?   Michel: Yes.   Carolyn: But your study seems to tell us that that assumption, that everyone's receiving treatment and still having high blood pressure, may need to be questioned, so please tell us a little bit more about what you found.   Michel: This is a clinical trial where we compared the effect of renal denervation to medical treatment, optimal medical treatment. We standardized the anti-hypertensive treatment in the cohort of patients with resistant hypertension, and then we followed them on a monthly basis with home blood pressure monitoring. We also increased the intensity of the treatment every month after randomization between renal denervation against nothing, because this is a probe trial, it is not a double blind trial. We gave them the same treatment in both arms. At the end of the many study we demonstrated that there was 6 millimeter of difference, in terms of ABPM, in favor of renal denervation, against the same medical treatment alone.     However, because this trial was an open trial, it was open to a Hawthorne effect, and the possibility that patients or doctors behave differently in each arm of the study. Those having renal denervation may be more adherent to the treatment, and those not being given the new therapy, not being really adherent to treatment. This was an issue, so we specified analysis. We also measured drug levels in urine after six months of followup, and also assessed the exposure to each individual using a peptide in urine, which is N-acetyl-serylaspartyl-lysyl-proline (AcSDKP)/creatinine.     What we found after six months of followup in patients who really participated to this trial, they were willing to participate to the study, they signed an informed consent where it was written that, indeed, we will monitor drug levels. They knew that we would do this. They also knew that we will follow them very carefully every month, et cetera, that we'll provide them home blood pressure monitor for free. They had access to the same doctor, same nurse, same everything. They could arrive at the time they wanted in the morning for being investigated. After six months of followup we found that more than half of these patients did not take correctly their treatment, and even 15% of them, in reality, took zero medication over seven medications. This was a major, major surprise for us in this trial.   Carolyn: I think that's one of the most significant findings, even in a trial setting, that is such a lot of non-adherents, anti-habitants, of therapy. It really makes us question when we say someone has resistant hypertension, is it really that, or do we have just a very non-compliant patient?   Michel: Yes.   Carolyn: Because it can only be worse in the real-world setting, isn't it? Congratulations, that was a very striking message to me as well. What was the other main finding that you wanted to ... ?   Michel: The other finding was that the rate of non-adherence was similar in both arms. That there was absolutely no influence of being randomized to the renal denervation group or the medical treatment group only. This means that the patients were not influenced, and other physicians behaved similarly in both arms. Because at the end you have exactly the same rate of non-adherence to treatment. This is also very important.   Carolyn: Yes, indeed. Wanpen, I was wondering what your thoughts were, and take-home messages from this paper. We definitely thought it was significant in the editorial board because you even commissioned a wonderful editorial by Dr. David Calhoun on this. What are your thoughts?   Wanpen: In the United States, using the same technique, we found as much non-adherence. I think there is a lot that we need to do and to understand what caused non-adherence. The patient should not be the only party that's to blame. I think that the doctor's as much of a culprit here to try to tease out what's the barrier to the treatment. Also, as pointed out by Dr. Calhoun, is that although the trials show improvement in blood pressure in both groups, at the end number of medications of patients in resistant hypertension, they require to take four to five drugs to get the blood pressure under control. I think this is going to be a lifelong continuing medication treatment that the physicians have to face, and to deal with the adherence problem as well. Just lastly, I think that although people believe that doing drug levels is only for research purpose, but many people don't realize that actually many drug levels for anti-hypertensive drugs actually is clinical available and can be ordered. It takes a little bit more effort to order it, but it can be done, and actually our center has been doing that already anyway.   Carolyn: Wow. I cannot say that my center has been doing that in Asia, but I really have to admit that this paper made me think about it. Especially the editorial when he highlights it, the very unique information that is provided by actually measuring the blood levels. Michel, you were nodding your head vigorously when Wanpen was saying that we should not just blame the patient. Tell me, what are your thoughts, and how does this affect your clinical practice?   Michel: I fully agree with Wanpen. We have to now integrate the fact that it's accessible, you can measure drug levels through technology, with mass spectrometry, et cetera. This is very important to integrate and to change our paradigm that we have to put in our brain. We have to monitor drug levels. Using this technology we have to establish a partnership with the patient.     I think the truth, also, is somewhere, as Wanpen said, we are also culprits. If patients do not take their treatment, okay, there may be some benefit and e have to look why they are not taking pill treatment, but also we are culprits because we don't listen to them, we don't take enough time, et cetera, et cetera. But I think patients should not be only blamed, so it opens a new possibility to discuss with the patient about the fact that we didn't find the drug in levels in their urine, et cetera.     However, taking into account that there will be this toothbrush effect, that is, "Patient, brush your teeth when you go to see the dentist," you'll take the pills when you go to see the doctor so you can be treated. This is one of the difficulties. However I think it's a new possibility to discuss with the patient of his or her difficulties in taking the pills. It gives us the opportunity to discuss, to take time with our patients.   Carolyn: It's really fascinating, you're talking from a system based in Europe. You're based in Paris.   Michel: Yes.   Carolyn: Wanpen just said that she's doing it, and she's based in the US. Do you now routinely, maybe, monitor these medication levels?   Michel: Yes, yes, yes.   Carolyn: Wow.   Michel: In the hospital we have these mass spectrometer platforms, so we have access to this, and we are working with the house authority to have the reimbursement. Because I think it's important, because if it's not reimbursed there is also a problem.   Carolyn: Of course.   Michel: We are working to see how it could be reimbursed for labs doing these measurements.   Carolyn: But this is for maybe selected resistant hypertensive patients that are difficult to ... ?   Michel: Yes, absolutely. Those very difficult to manage. I think, as a rule of thumb, that after four or five drugs given to the patient, if the patient-   Carolyn: Yeah, we should start questioning, are they taking it.   Michel: If the patients do not have secondary hypertension, we should really start questioning ourself whether they are taking or not the treatment, even if they are looking right in your eyes and telling you, "Yes, doctor, I'm taking all the pills."   Carolyn: Wanpen, how about the reimbursement issues and things like that in the United States? How are you getting it done in your institution?   Wanpen: Actually the coding for doing drug levels, it's actually generic. It's the same coding for Digoxin or Cyclosporine. They actually don't care about what the name of the drug. Strangely, they're coded by the technique, so that's how we go with it, but we have to put in miscellaneous "other" for, we wanted to test for this. That's how we get around it.   Carolyn: Do you do that again routinely, or in selected patients that are difficult to manage hypertensive?   Wanpen: Obviously we have to be selective, so we select from people who we would suspect are non-adherent, but they say they're taking it. But if they already came in and made that they're not taking the drug, there's no point doing that for the clinical purpose. We're doing it for people who we suspect it, and we use it the way ... Actually we shall describe very well, not only just to find what drug they're not taking, because when they're not taking, only about 30% are not taking everything, about 20% not taking one or two drugs. When we drill down to that drug they say, "I have side effects to beta blocker and I don't want to tell my physician that I have problems taking it, but I just not take it." I think that's what led us to pinpoint the problem a little bit better with this technique.   Carolyn: What a lot of practical advice, and congratulations once again for very, very meaningful findings. I learned a lot this time. I don't do this, and so I'm definitely going to think about this much more because of your work. Thank you very much Wanpen, Michel.     And thank you, listeners, for tuning in this time. Remember, you're listening to circulation on the run. Listen in again next week. Thanks.    

Referrals from FDN Get an online scheduling/calendar link Business accounts, dealing with banks Starting over with FDN from 2013  How to sign up first clients when I have no testimonials or real life experience Allopathic benefits of MRT Why run all 5 labs "I don't know enough" Cyclosporine and Genova IP and 401H Collecting saliva for 205 with very dry mouth

The post Cyclosporine ( Cyclosporine) appeared first on NURSING.com.

Commentary by Dr. Valentin Fuster

A pharmacy student presents a case about cyclosporine.

Background. Long-term results of prospective randomized trials comparing triple immunosuppressive strategies combining tacrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart transplantation (HTX) are rarely published. Therefore, we collected long-term follow-up data of an intervention cohort 10 years after randomization. Methods. Ten-year follow-up data of 60 patients included in a prospective, randomized trial between 1998 and 2000 were analyzed as intention-to-treat (TAC-MMF n=30; CsA-MMF n=30). Baseline characteristics were well balanced. Cardiac allograft vasculopathy (CAV) was graduated in accordance with the new ISHLT classification. Results. Survival at 1, 5, and 10 years was 96.7%, 80.0%, and 66.7% for TAC-MMF and 90.0%, 83.3%, and 80.0% for CsA-MMF (P=ns). Freedom from acute rejection (AR) was significantly higher in TAC-MMF versus CsA-MMF (65.5% vs. 21.7%, log-rank 8.3, P=0.004). Freedom from ISHLT >= CAV(1) after 5 and 10 years was in TAC-MMF 64.0% and 45.8%, and in CsA-MMF 36.0% (log-rank 3.0, P=0.085) and 8.0% (log-rank 9.0, P=0.003). No difference in long-term results for freedom from coronary angioplasty or stenting, renal dysfunction, diabetes mellitus, CMV infection, or malignancy was detected. Conclusion. Cross-over effects because of treatment switch may result in impairment of significance between the groups. The long-term analysis resulted in a significant difference in manifestation of CAV between the groups after 10 years. Less rejection in the TAC-group might have contributed to the lower incidence of CAV. Superior freedom from AR and CAV in the TAC-MMF group did not result in better long-term survival.

Das Handekzem ist ein sehr häufiges und weit verbreitetes Krankheitsbild. Vermutlich wurde es zum ersten mal im neunzehnten Jahrhundert beschrieben. Die sozioökonomischen Auswirkungen sind enorm, was sich vor allem mit der hohen Inzidenz und Prävalenz des Handekzems in der Bevölkerung begründet. Die unterschiedliche Schwere der Symptome hat auch gewaltige Auswirkungen auf die Lebensqualität des Patienten. Das Ziel dieser Doktorarbeit ist es, einen umfassenden und kritischen Überblick der gegenwärtigen Literatur und wissenschaftlichen Studien zur Epidemiologie, Pathogenese, Klassifizierung und Behandlung des chronischen Handekzems zu verschaffen. Zu diesem Zweck wurden elektronische Datenbanken nach wissenschaftlichen Studien und Berichten zum chronischen Handekzem durchsucht. Diese Suche ergab 16 unterschiedliche Behandlungsmethoden, die in 53 wissenschaftlichen Studien der letzten 40 Jahre erwähnt wurden. Die sorgfältige Auswertung dieser Studien ergibt, dass nur 8 der 53 Studien die Kriterien für doppelblinde randomisierte klinische Studien erfüllen. Fünf dieser erwähnten Studien benützen im Halbseitenversuch eine Hand des Patienten zur Intervention, während die andere als Kontrolle genutzt wird. Daher wurden insgesamt nur drei klinische Studien gefunden, die eine überschaubare Methodik zur Randomisierung der Patienten, doppelblinde Patienten und Versuchsleiter und separate Kontrollgruppen aufweisen können. Dies bedeutet, dass Daten einer Population von nur 1392 Patienten aus drei wissenschaftlichen Studien als Grundlage für die Behandlung dieses weit verbreiteten Krankheitsbildes angewendet werden können. Ferner werden die Unzulänglichkeiten der Studien diskutiert und Empfehlungen gemacht, um diese in Zukunft zu vermeiden. Zusätzlich wurden Patientendaten von 107 Patienten mit refraktärem Handekzem, die mit Creme-PUVA-Photochemotherapie in der Lichttherapie-Abteilung in der Hautklinik der Heinrich Heine Universität in Düsseldorf behandelt wurden, gesammelt und ausgewertet. Diese Daten wurden schliesslich als Studie bei einer wissenschaftlichen Fachzeitschrift eingereicht. Vollständiger oder teilweiser Rückgang des Handekzems wurde bei 78% der behandelten Patienten bemerkt. Die Therapie bewies sich als wirkungsvoller an Patienten mit hyperkeratotisch-rhagadiformem (85%) und dyshidrotischem (81.1%) Handekzem als bei Patienten, die unter dem atopischen (66.67%) oder Kontaktekzem (20%) litten. Vollständiger oder teilweiser Rückgang des Handekzems wurde bei 83% der männlichen und bei 72.7% der weiblichen Patienten bemerkt. Zwei der Patienten klagten über Hautrötungen als Nebeneffekt der Bestrahlungstherapie. Diese Ergebnisse unterstreichen die Bedeutung von Creme-PUVA-Photochemotherapie als wirksame Behandlungsmethode von chronischem Handekzem. Dies gilt insbesondere für das günstige Sicherheitsprofil in Bezug auf kurz- und langfristige Nebenwirkungen. Abschliessend wird ein Vorschlag für einen Behandlungs-Algorithmus für das chronische Handekzem diskutiert. Hierfür werden die behandelten Studien als Grundlage genutzt. Die Bedeutung der regelmässigen Anwendung von Emollients und Kortikosteroiden sollte betont werden. Der nächste Schritt in der Behandlung sollte UV Bestrahlungstherapie oder Alitretinoin sein. Cyclosporine bieten sich als weiterer Schritt an, wobei Röntgenbestrahlung nur für behandlungsrefraktäre Fälle angewendet werden sollte.

Sun, 1 Jan 1984 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7934/1/7934.pdf Land, Walter; Castro, L. A.; Zöttlein, H.; Siebert, W.; Illner, Wolf-Dieter ddc:610, Med

Sun, 1 Jan 1984 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7922/1/7922.pdf Landgraf, R.; Abendroth, D.; Land, Walter; Illner, Wolf-Dieter

Sat, 1 Jan 1983 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7927/1/7927.pdf Zöttlein, H.; Siebert, W.; Land, Walter; Preis, D.; Graf, A.; Zink, R.; Mraz, W.; Illner, Wolf-Dieter

Sat, 1 Jan 1983 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7924/1/7924.pdf Zöttlein, H.; Zink, R.; Siebert, W.; Schneider, B.; Schmeller, N.; Hillebrand, Günther; Hammer, C.; Günther, K.; Castro, L. A.; Land, Walter; Illner, Wolf-Dieter